Abstract: This invention provides benzene derivatives, pharmaceutical formulations of those derivatives, and a method of using the derivatives for the treatment of inflammation in mammals.

Abstract: Inflammatory bowel disease is treated, and patients are protected from a relapse into active disease, by the administration of a compound chosen from a series of 3-phenyl-5-carboxypyrazoles and isothiazoles.

Abstract: A new microorganism, Streptomyces avermitilis subspecies niger NRRL 21005, and processes using the microorganism for producing known avermectins are provided.

Abstract: New hapalindole-type alkaloids called A89271 A-F and I are antifungal and antitumor agents. Methods for preparing them and for preparing hapalindoles G and H by culturing the blue-green alga Fischerella ambigua ATCC 55210 are provided. Methods for preparing A89271 factors B and F by culturing the blue-green alga Hapalosiphon hibernicus ATCC 55225 and a biologically pure culture of this alga are also provided. Further provided are methods and compositions for the inhibition of fungal growth and the treatment of susceptible neoplasms.

Abstract: Intermediates to 1-phenyl-3-naphthalenyloxypropanamines which selectively inhibit serotonin uptake and are useful for treating a variety of disorders linked to decreased neurotransmission of serotonin in mammals.

Abstract: Newly-discovered antibiotic A10255 factors B, C, E, and F are produced by submerged aerobic fermentation of previously-unknown Streptomyces gardneri strain NRRL 15922, or an A10255-producing variant, mutant or recombinant thereof. The antibiotics are active against a wide variety of pathogenic bacteria, and also enhance feed-utilization efficiency in chickens, weanling pigs and cattle.

Abstract: The present invention provides novel ring-substituted 2-amino-1,2,3,4-tetrahydronaphthalenes, 3-aminochromanes, and 3-aminothiochromanes, including their corresponding sulfoxides and sulfones, which ring-substituted compounds exhibit agonist activity at the serotonin 1A receptor.

Abstract: Newly discovered lipoglycopeptide antibiotic A84575 complex, comprising factors A, B, C, D, E, F, G, and H, is produced by submerged aerobic fermentation of a culture selected from Streptosporangeum carneum NRRL 18437, Streptosporangeum carneum NRRL 18505 or an A84575-producing mutant thereof. The antibiotics are active against Gram-positive bacteria.

Abstract: A pharmaceutical compound of the formula ##STR1## in which n is 0, 1 or 2 and R.sup.1 is attached at any of the positions 5, 6, 7, 8, 9 or 10, and each R.sup.1 is halo, trifluoromethyl, C.sub.1-4 alkoxy, hydroxy, nitro, C.sub.1-4 alkyl, C.sub.1-4 alkylthio, hydroxy-C.sub.1-4 alkyl, hydroxy-C.sub.1-4 alkoxy, trifluoromethoxy, carboxy, --COOR.sup.5 where R.sup.5 is an ester group, --CONR.sup.6 R.sup.7 or --NR.sup.6 R.sup.7 where R.sup.6 and R.sup.7 are each hydrogen or C.sub.1-4 alkyl; R.sup.2 is phenyl, naphthyl or heteroaryl selected from thienyl, pyridyl, benzothienyl, quinolinyl, benzofuranyl or benzimidazolyl, said phenyl, naphthyl and heteroaryl groups being optionally substituted, or R.sup.2 is furanyl optionally substituted with C.sub.1-4 alkyl; R.sup.3 is nitrile, carboxy, --COOR.sup.8 where R.sup.8 is an ester group, --CONR.sup.9 R.sup.10 where R.sup.9 and R.sup.10 are each hydrogen or C.sub.1-4 alkyl, or R.sup.11 SO.sub.2 -- where R.sup.11 is C.sub.1-4 alkyl or optionally substituted phenyl; and R.

Abstract: This invention provides compounds which are useful in the preparation of AMPA receptor antagonists.

Abstract: The invention provides compounds of the formula ##STR1## wherein R* is a group of the formula ##STR2## wherein R and R.sup.0 are individually C.sub.1 -C.sub.6 alkyl groups or together form a ring consisting of the nitrogen atom to which they are attached and two to seven carbon atoms, said ring optionally substituted by one or more C.sub.1 -C.sub.6 alkyl and/or C.sub.1 -C.sub.6 substituted alkyl groups;Q and Q' are individually hydrogen, C.sub.1 -C.sub.6 alkyl, or when taken together form a divalent radical of the formula --CH.dbd.CH--CH.dbd.CH--;A and A' together form a group of the formula ##STR3## wherein R.sup.2 is hydrogen or a carboxy-protecting group; X is oxygen; R.sup.1 is hydrogen, hydroxy, halo, C.sub.1 -C.sub.6 alkoxy, C.sub.1 -C.sub.6 alkyl, C.sub.1 -C.sub.6 substituted alkyl, C.sub.1 -C.sub.6 alkylthio, C.sub.1 -C.sub.6 substituted alkylthio, C.sub.7 -C.sub.12 phenylalkyl, C.sub.7 -C.sub.12 substituted phenylalkyl, phenyl or substituted phenyl; a group of the formula--COR.sup.3wherein R.sup.

Abstract: This invention relates to N-hydroxy-N-[3-[2-(4'-halophenylthio)phenyl]prop-2-enyl]ureas, formulations containing those compounds and methods of using such compounds as 5-lipoxygenase inhibiting agents.

Abstract: Provided are methods of treating inflammation, arthritis and muscular dystrophy and preventing ischemia-induced cell damage employing certain phenol and benzamide compounds.

Abstract: This invention provides a method of treating diabetic complications in mammals which comprises the administration of a compound of the Formula I: ##STR1## in which n, R.sub.1, R.sub.2, R.sub.3, and R.sub.4 are variables.

Abstract: This invention provides N-alkyl-3-phenyl-3-(2-substituted phenoxy)propylamines which are useful to treat neurological disorders associated with norepinephrine imbalance.

Abstract: A compound of the formula ##STR1## in which R.sup.1 is hydrogen, halo, C.sub.1-4 alkyl, C.sub.1-4 alkoxy, nitrile, optionally protected carboxy, optionally protected tetrazolyl, trihalomethyl, hydroxy-C.sub.1-4 alkyl, aldehydo, --CH.sub.2 Z, --CH.dbd.CH--Z or --CH.sub.2 CH.sub.2 Z where Z is optionally protected carboxy or optionally protected tetrazolyl; R.sup.2 is halo, nitrile, an optionally protected acid group or --CONR.sup.7 R.sup.8 where R.sup.7 and R.sup.8 are each hydrogen or C.sub.1-4 alkyl; R.sup.3 and R.sup.4 are each hydrogen, C.sub.1-4 alkyl, optionally substituted phenyl, or C.sub.1-4 alkyl substituted by --CONR.sup.7 R.sup.8 or an optionally protected acid group; R.sup.5 is ##STR2## where W is --CH.dbd.CH--, --CH.dbd.N--, --N.dbd.CH--, --O-- or --S--, R.sup.9 is hydrogen, halo, C.sub.1-4 alkyl, C.sub.1-4 alkoxy or trihalomethyl, and R.sup.10 is hydrogen, C.sub.1-4 alkyl, C.sub.2-6 alkenyl, C.sub.3-6 cycloalkyl or C.sub.1-4 alkyl-C.sub.3-6 cycloalkyl; R.sup.6 is hydrogen or C.sub.

Abstract: Provided is a method for treating Type I diabetes in mammals utilizing certain phenol and benzamide compounds.

Abstract: The present invention provides a process for preparing a 4-hydroxypyrrolo[2,3-d]pyrimidine derivative of the formula ##STR1## wherein R is NHC*H(COOR.sup.1)CH.sub.2 CH.sub.2 COOR.sup.1 or OR.sup.1 ;R.sup.1 is H or a carboxyl protecting group;the configuration about the carbon atom designated * is L;n is 0 or 1; andA is an aryl group optionally having, in addition to the COR substituent, one or two substituents selected from the group consisting of halo, hydroxy, C.sub.1 -C.sub.4 alkyl and C.sub.1 -C.sub.4 alkoxy; or a salt thereof, which comprises(a) halogenating a compound of the formula ##STR2## wherein R, R.sup.1, A and * are as defined above;j is 0 or 1; and(b) reacting 2,4-diamino-6-hydroxypyrimidine, or a salt thereof, with the reaction product from step (a), in the presence of a polar solvent.

Abstract: Fermentation product A87689 is produced by a strain of Amycolatopsis mediterranei selected from NRRL 18815 and NRRL 18851, or an A87689-producing mutant thereof. A87689, its C.sub.1-6 -alkyl ether and C.sub.1-6 -alkanoyl ester derivatives and pharmaceutically acceptable salts thereof are phospholipase A.sub.2 inhibitors that are useful as antiinflammatory agents. Fermentation products known as BU-3889V, its components and pharmaceutically acceptable salts thereof, are phospholipase A.sub.2 inhibitors that are also useful as antiinflammatory agents.

Abstract: Improved processes for producing a polyether antibiotic compound represented by A82810 comprising: (1) cultivating Actinomadura fibrosa sp. nov. NRRL 18348 or Actinomadura sp. NRRL 18880, (2) feeding acid hydrolyzed casein at a rate from about 2.50-7.50 gm/L/day, (3) feeding glucose at a rate from about 2.50-7.50 gm/L/day, and (4) feeding propionate at a rate from about 0.50-1.5 gm/L/day to the appropriate culture medium during fermentation, are provided.